Table 1.
Baseline Characteristics of Included Studies [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
| Author, Year | Country | Study Design | No. of Subjects (n) | Gender | Mean Age (year) | Vaccine Received (n) | |||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Mean | SD | Pfizer BioNTech | Moderna | ||||
| Abellan C et al., 2021 [92] | Switzerland | Case Series | 3 | 3 | 0 | 28.67 | 14.15 | 0 | 3 |
| Ahmed SK, 2022 [91] | Iraq | Case Series | 5 | 5 | 0 | 27.80 | 7.36 | 3 | 2 |
| Aikawa T et al., 2022 [89] | Japan | Case Report | 1 | 1 | 0 | 20.00 | NA | 0 | 1 |
| Alania-Torres E et al., 2021 [90] | Spain | Case Report | 1 | 1 | 0 | 28.00 | NA | 1 | 0 |
| Albert E et al., 2021 [88] | USA | Case Report | 1 | 1 | 0 | 24.00 | NA | 0 | 1 |
| Ammirati E et al., 2021 [87] | Italy | Case Report | 1 | 1 | 0 | 56.00 | NA | 1 | 0 |
| Aviram G et al., 2022 [86] | Israel | Case Series | 4 | 4 | 0 | 29.25 | 6.99 | 4 | 0 |
| Bautista Garcia J et al., 2021 [85] | Spain | Case Report | 1 | 1 | 0 | 39.00 | NA | 1 | 0 |
| Bengel C et al., 2022 [84] | Germany | Case Series | 2 | 2 | 0 | 21.50 | 2.12 | 0 | 2 |
| Bews H et al., 2022 [83] | Canada | Case Series | 9 | 8 | 1 | 23.89 | 5.35 | 2 | 7 |
| Cereda A et al., 2021 [79] | Italy | Case Report | 1 | 1 | 0 | 21.00 | NA | 1 | 0 |
| Chachar T et al., 2021 [80] | Bahrain | Case Report | 1 | 1 | 0 | 24.00 | NA | 1 | 0 |
| Chamling B et al., 2021 [81] | Germany | Case Series | 2 | 2 | 0 | 22.50 | 3.53 | 2 | 0 |
| Chellapandian SB et al., 2022 [82] | Qatar | Case Report | 1 | 1 | 0 | 22.00 | NA | 0 | 1 |
| Chow BT and Lai CK, 2022 [77] | Canada | Case Report | 1 | 0 | 1 | 45.00 | NA | 0 | 1 |
| Cimaglia P et al., 2022 [78] | Italy | Case Report | 1 | 1 | 0 | 24.00 | NA | 1 | 0 |
| D’Angelo T et al., 2021 [76] | Italy | Case Report | 1 | 1 | 0 | 30.00 | NA | 1 | 0 |
| Deb A et al., 2021 [75] | USA | Case Report | 1 | 1 | 0 | 67.00 | NA | 0 | 1 |
| Diaz GA et al., 2021 [74] | USA | Retrospective Study | 20 | 15 | 5 | 36.00 | 16.30 | 9 | 11 |
| Dickey JB et al., 2021 [73] | US | Case Series | 3 | 3 | 0 | NR | NR | 2 | 1 |
| Dlewati M et al., 2022 [72] | USA | Case Report | 1 | 1 | 0 | 48.00 | NA | 0 | 1 |
| Gautam N et al., 2021 [71] | USA | Case Report | 1 | 1 | 0 | 66.00 | NA | 1 | 0 |
| Habedank D et al., 2022 [70] | Germany | Case Report | 1 | 1 | 0 | 60.00 | NA | 0 | 1 |
| Habib MB et al., 2021 [69] | Qatar | Case Report | 1 | 1 | 0 | 37.00 | NA | 1 | 0 |
| Jahnke C et al., 2022 [68] | Germany | Case Series | 2 | 2 | 0 | 31.50 | 14.85 | 1 | 1 |
| Kaneta K et al., 2022 [67] | Japan | Case Report | 1 | 1 | 0 | 25.00 | NA | 0 | 1 |
| Kaul R et al., 2021 [66] | USA | Case Series | 2 | 2 | 0 | 24.50 | 4.95 | 1 | 1 |
| Kawakami T et al., 2022 [65] | Japan | Case Report | 1 | 0 | 1 | 45.00 | NA | 0 | 1 |
| Kim HW et al., 2021 [64] | USA | Case Series | 4 | 3 | 1 | 38.25 | 21.98 | 2 | 2 |
| Kim IC et al., 2021 [61] | Korea | Case Study | 1 | 1 | 0 | 24.00 | NA | 1 | 0 |
| King WW et al., 2021 [63] | USA | Case Series | 4 | 3 | 1 | 25.50 | 4.79 | 1 | 3 |
| Koizumi T et al., 2021 [60] | Japan | Case Study | 2 | 2 | 0 | 24.50 | 3.54 | 0 | 2 |
| Korosoglou G et al., 2022 [62] | Germany | Case Report | 1 | 1 | 0 | 21.00 | NA | 1 | 0 |
| Larson KF et al., 2021 [59] | USA and Italy | Case Series | 8 | 8 | 0 | 31.63 | 11.99 | 5 | 3 |
| Lee CH and Kong EJ, 2022 [58] | South Korea | Case Report | 1 | 1 | 0 | 22.00 | NR | 0 | 1 |
| Levin D et al., 2021 [56] | Israel | Case Series | 7 | 7 | 0 | 20.43 | 2.07 | 7 | 0 |
| Maeda M et al., 2022 [19] | Japan | Case Report | 1 | 1 | 0 | 29.00 | NA | 0 | 1 |
| Maki H et al., 2022 [54] | Japan | Case Report | 1 | 0 | 1 | 20.00 | NA | 0 | 1 |
| Manfredi R et al., 2022 [57] | Italy | Case Series | 2 | 2 | 0 | 21.50 | 4.95 | 1 | 1 |
| Mansour J et al., 2021 [55] | USA | Case Series | 2 | 1 | 1 | 23.00 | 2.83 | 0 | 2 |
| Marhshall M et al., 2021 [16] | USA | Case Report | 1 | 1 | 0 | 18.00 | NA | 1 | 0 |
| Matta A et al., 2021 [53] | USA | Case Report | 1 | 1 | 0 | 27.00 | NA | 1 | 0 |
| Mengesha B et al., 2022 [52] | Israel | Case Report | 1 | 0 | 1 | 43.00 | NA | 1 | 0 |
| Meyer-Szary J et al., 2022 [51] | Poland | Case Series | 1 | 1 | 0 | 29.00 | NA | 0 | 1 |
| Miqdad MA et al., 2021 [46] | Saudi Arabia | Case Report | 1 | 1 | 0 | 18.00 | NA | 1 | 0 |
| Montgomery J et al. 2021 [50] | USA | Retrospective case series | 23 | 23 | 0 | 25.00 | 7.75 | 7 | 16 |
| Mouch S et al., 2021 [49] | Israel | Case Series | 4 | 4 | 0 | 29.50 | 10.97 | 4 | 0 |
| Murakami Y et al., 2022 [48] | Japan | Case Series | 2 | 2 | 0 | 65.00 | 7.78 | 2 | 0 |
| Muthukumar A et al., 2021 [47] | USA | Case Report | 1 | 1 | 0 | 52.00 | NA | 0 | 1 |
| Nagasaka T et al., 2022 [45] | Japan | Case Report | 1 | 1 | 0 | 23.00 | NA | 1 | 0 |
| Nevet A et al., 2021 [38] | Israel | Case Series | 3 | 3 | 0 | 24.33 | 4.51 | 3 | 0 |
| Nguyen TD et al., 2021 [37] | Germany | Case Report | 1 | 1 | 0 | 20.00 | NA | 0 | 1 |
| Nunn S et al., 2022 [44] | Germany | Case Series | 1 | 0 | 1 | 31.00 | NA | 1 | 0 |
| Ohnishi M et al., 2022 [43] | Japan | Case Report | 1 | 1 | 0 | 26.00 | NA | 1 | 0 |
| Onderko L et al., 2021 [42] | USA | Case Series | 3 | 3 | 0 | 29.67 | 5.69 | 2 | 1 |
| Parmar K et al., 2022 [41] | USA | Case Series | 4 | 3 | 1 | 29.00 | 16.06 | 0 | 4 |
| Patel YR et al., 2021 [40] | USA | Case Series | 5 | 5 | 0 | 24.60 | 7.30 | 4 | 1 |
| Patrignani A et al., 2021 [39] | Italy | Case Report | 1 | 1 | 0 | 56.00 | NA | 1 | 0 |
| Sano M et al., 2022 [36] | Japan | Case Report | 1 | 1 | 0 | 20.00 | NA | 0 | 1 |
| Schmitt P et al., 2021 [29] | France | Case Report | 1 | 1 | 0 | 19.00 | NA | 1 | 0 |
| Shaw KE et al., 2021 [35] | USA | Case Series | 2 | 1 | 1 | 27.50 | 4.95 | 1 | 1 |
| Shiyovich A et al., 2022 [34] | Israel | Case Series | 4 | 3 | 1 | 27.25 | 11.64 | 4 | 0 |
| Shumkova M et al., 2021 [33] | Bulgaria | Case Report | 1 | 1 | 0 | 23.00 | NA | 1 | 0 |
| Singh B et al., 2021 [32] | USA | Case Study | 1 | 1 | 0 | 24.00 | NA | 1 | 0 |
| Sokolska J et al., 2021 [31] | Poland | Case Report | 1 | 1 | 0 | 21.00 | NA | 1 | 0 |
| Starekova J et al., 2021 [30] | USA | Case Series | 4 | 3 | 1 | 27.25 | 9.36 | 2 | 2 |
| Tailor P et al., 2021 [22] | USA | Case Report | 1 | 1 | 0 | 44.00 | NA | 0 | 1 |
| Verma A et al., 2021 [23] | USA | Case Series | 2 | 1 | 1 | 43.50 | 2.12 | 1 | 1 |
| Vidula MK et al., 2021 [24] | USA | Case Report | 2 | 2 | 0 | 18.50 | 0.71 | 1 | 1 |
| Viskin D et al., 2021 [21] | Israel | Case Series | 8 | 7 | 1 | NR | NR | 8 | 0 |
| Watkins K et al., 2021 [28] | USA | Case Report | 1 | 1 | 0 | 20.00 | NA | 1 | 0 |
| Williams CB et al., 2021 [27] | Canada | Case Report | 1 | 1 | 0 | 34.00 | NA | 0 | 1 |
| Wong J et al., 2022 [26] | Australia | Case Report | 1 | 1 | 0 | 20.00 | NA | 1 | 0 |
| Wu B et al., 2022 [25] | USA | Case Report | 1 | 1 | 0 | 40.00 | NA | 1 | 0 |
| Yen KC et al., 2022 [20] | Taiwan | Case Report | 1 | 1 | 0 | 32.00 | NA | 0 | 1 |
NA: Not applicable, NR: Not reported, SD: Standard deviation.